Total Payments
$29,321
2024 Payments
$3,986
Companies
29
Transactions
600
Medicare Patients
983
Medicare Billing
$37,428
Payment Breakdown by Category
Other$12,000 (40.9%)
Food & Beverage$10,034 (34.2%)
Research$4,735 (16.1%)
Travel$2,478 (8.5%)
Education$54.99 (0.2%)
Gifts$20.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,000 | 6 | 40.9% |
| Food and Beverage | $10,034 | 569 | 34.2% |
| Unspecified | $4,735 | 12 | 16.1% |
| Travel and Lodging | $2,478 | 11 | 8.5% |
| Education | $54.99 | 1 | 0.2% |
| Gift | $20.00 | 1 | 0.1% |
Payments by Type
General
$24,587
588 transactions
Research
$4,735
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $14,468 | 77 | $0 (2024) |
| Eli Lilly and Company | $3,105 | 2 | $0 (2024) |
| Amgen Inc. | $2,604 | 156 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,068 | 36 | $0 (2024) |
| ABBVIE INC. | $1,866 | 130 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1,462 | 11 | $0 (2018) |
| GENZYME CORPORATION | $660.06 | 22 | $0 (2020) |
| Lilly USA, LLC | $373.37 | 24 | $0 (2022) |
| Mallinckrodt Enterprises LLC | $346.69 | 9 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $338.09 | 15 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,986 | 49 | Eli Lilly and Company ($3,105) |
| 2023 | $1,114 | 66 | Amgen Inc. ($538.06) |
| 2022 | $1,526 | 87 | Amgen Inc. ($580.24) |
| 2021 | $1,006 | 73 | Amgen Inc. ($387.04) |
| 2020 | $1,305 | 81 | AbbVie Inc. ($366.37) |
| 2019 | $2,798 | 84 | GlaxoSmithKline, LLC. ($1,651) |
| 2018 | $7,686 | 72 | PFIZER INC. ($4,895) |
| 2017 | $9,901 | 88 | PFIZER INC. ($9,118) |
All Payment Transactions
600 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.54 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $6.85 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $118.93 | General |
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $33.71 | General |
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $29.11 | General |
| Category: Immunology | ||||||
| 10/30/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: IMMUNOLOGY | ||||||
| 10/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $9.41 | General |
| Category: Inflammation | ||||||
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS | ||||||
| 09/06/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $10.57 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 08/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: IMMUNOLOGY | ||||||
| 08/23/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $26.50 | General |
| Category: Immunology | ||||||
| 08/22/2024 | Eli Lilly and Company | — | — | In-kind items and services | $104.58 | Research |
| Study: EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | ||||||
| 08/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: IMMUNOLOGY | ||||||
| 07/30/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $30.24 | General |
| 07/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: IMMUNOLOGY | ||||||
| 07/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.88 | General |
| Category: IMMUNOLOGY | ||||||
| 07/20/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: IMMUNOLOGY | ||||||
| 07/17/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $6.09 | General |
| Category: Inflammation | ||||||
| 07/16/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Inflammation | ||||||
| 07/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: IMMUNOLOGY | ||||||
| 06/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.16 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS | Eli Lilly and Company | $3,000 | 1 |
| A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO | GlaxoSmithKline, LLC. | $1,613 | 9 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $104.58 | 1 |
| Safety,Immunogenicity, and Dose ranging Study of Inactivqatzed Zika Virus vaccine in Healthy Adults | Takeda Pharmaceuticals U.S.A., Inc. | $16.93 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 14 | 983 | 1,290 | $64,004 | $37,428 |
Total Patients
983
Total Services
1,290
Medicare Billing
$37,428
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 134 | 134 | $23,282 | $16,941 | 72.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 90 | 95 | $10,737 | $8,132 | 75.7% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder | Office | 2020 | 47 | 329 | $9,870 | $5,797 | 58.7% |
| 86480 | Tuberculosis test | Office | 2020 | 18 | 18 | $1,800 | $1,116 | 62.0% |
| 86200 | Measurement of antibody for rheumatoid arthritis assessment | Office | 2020 | 86 | 86 | $2,150 | $1,103 | 51.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2020 | 94 | 97 | $5,335 | $1,016 | 19.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 94 | 97 | $2,425 | $747.39 | 30.8% |
| 86225 | Measurement of dna antibody | Office | 2020 | 47 | 47 | $1,175 | $634.64 | 54.0% |
| 86038 | Screening test for autoimmune disorder | Office | 2020 | 47 | 47 | $1,175 | $558.42 | 47.5% |
| 86431 | Rheumatoid factor level | Office | 2020 | 80 | 80 | $1,600 | $449.00 | 28.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 106 | 115 | $2,300 | $342.51 | 14.9% |
| 85652 | Red blood cell sedimentation rate, to detect inflammation | Office | 2020 | 98 | 103 | $1,545 | $275.91 | 17.9% |
| 87340 | Detection test for hepatitis b surface antigen | Office | 2020 | 19 | 19 | $380.00 | $196.27 | 51.7% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2020 | 23 | 23 | $230.00 | $119.14 | 51.8% |
About Dr. Paul Pickrell, MD
Dr. Paul Pickrell, MD is a Rheumatology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114935418.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Pickrell, MD has received a total of $29,321 in payments from pharmaceutical and medical device companies, with $3,986 received in 2024. These payments were reported across 600 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($12,000).
As a Medicare-enrolled provider, Pickrell has provided services to 983 Medicare beneficiaries, totaling 1,290 services with total Medicare billing of $37,428. Data is available for 1 year (2020–2020), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Austin, TX
- Active Since 08/03/2006
- Last Updated 05/20/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1114935418
Products in Payments
- XELJANZ (Drug) $14,408
- Enbrel (Biological) $2,059
- V160 (Biological) $1,462
- RINVOQ (Biological) $794.01
- KEVZARA (Drug) $624.28
- BENLYSTA (Biological) $424.61
- ACTHAR (Biological) $366.31
- TALTZ (Drug) $343.84
- RINVOQ (Drug) $302.16
- TAVNEOS (Drug) $299.31
- Humira (Biological) $252.27
- OFEV (Drug) $235.04
- COSENTYX (Biological) $234.92
- SKYRIZI (Biological) $205.41
- Otezla (Drug) $191.80
- Tymlos (Biological) $181.06
- SIMPONI ARIA (Biological) $170.69
- LUPKYNIS (Drug) $161.38
- HUMIRA (Biological) $140.79
- RHEUMATOID ARTHRITIS DISEASE (Drug) $131.20
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Austin
Dr. Robert Koval, Md, MD
Rheumatology — Payments: $67,062
Rheumatology $67,062
Joseph Martinez, Md, MD
Rheumatology — Payments: $21,904
Rheumatology $21,904
Dr. Louis Robinett, M.d, M.D
Rheumatology — Payments: $6,520
Rheumatology $6,520
Marco Lopez Velazquez, M.d, M.D
Rheumatology — Payments: $3,941
Rheumatology $3,941
Sonia Yousuf, Md, MD
Rheumatology — Payments: $2,974
Rheumatology $2,974
Dr. Samir Patel, M.d, M.D
Rheumatology — Payments: $1,565
Rheumatology $1,565